Kidney cancer research highlights from ASCO GU 2025
Every year, researchers from around the world gather at a [...]
Multi-million-pound UK-wide research into cancer immunotherapy
The Francis Crick Institute and The Royal Marsden NHS Foundation [...]
ASCO GU 2023: Further information from the cabozantinib plus nivolumab study
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
Potential biomarkers for kidney cancer
Immunotherapy medicines have dramatically changed the way advanced (metastatic) kidney [...]
Biomarkers for immunotherapy outcomes for kidney cancer
This review in the journal Cereus is very technical, but [...]
Prediction of outcomes in patients with small renal masses
Most patients with small renal masses can be monitored safely [...]
C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer
A biomarker is a biological molecule found in blood, other body [...]
Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab
Neutrophils and eosinophils are white blood cells. In this study, [...]
Samra Turajlic, Action Kidney Cancer trustees, talks about the forthcoming IKCS meeting
Samra Turajlic, Medical Oncologist, Action Kidney Cancer trustee, and member [...]
Biomarker for predicting disease recurrence in non-metastatic papillary kidney cancer
A biomarker is a biological molecule found in blood, other [...]
